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Summary
 
When Epstein-Barr virus (EBV) infects B cells in vitro, the result is a proliferating lymphoblast
that expresses at least nine latent proteins. It is generally believed that these cells are rigorously
controlled in vivo by cytotoxic T cells. Consistent with this, the latently infected cells in the
peripheral blood of healthy carriers are not lymphoblasts. Rather, they are resting memory B
cells that are probably not subject to direct immunosurveillance by cytotoxic T lymphocytes
(CTLs). When patients become immunosuppressed, the viral load increases in the peripheral
blood. The expansion of proliferating lymphoblasts due to the suppressed CTL response is be-
lieved to account for this increase and is considered to be a major risk factor for posttransplant
lymphoproliferative disease (PTLD) and AIDS-associated B cell lymphoma. Here we show that
there is an increase in the numbers of latently infected cells in the peripheral blood of immuno-
suppressed patients. However, the cells are not proliferating lymphoblasts. They are all latently
infected, resting, memory B cells—the same population of infected cells found in the blood of
healthy carriers. These results are discussed in the context of a model for EBV persistence that
explains why PTLD is usually limited to the lymph nodes.
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E
 
pstein-Barr virus (EBV) is a B lymphotropic herpesvi-
rus (for a general review, see reference 1). It will la-
tently infect any resting primary B cell in vitro, irrespective
of its phenotype. As a consequence, the resting B cell be-
comes activated into a latently infected lymphoblast that
will proliferate indefinitely. This is referred to as the lym-
phoblastoid form of latency and is associated with the ex-
pression of nine known latent proteins (for a general re-
view, see reference 2), several of which have potent
growth-promoting activity and can act as oncogenes.
The pathogenic potential of EBV, suggested by the in
vitro studies, contrasts with the behavior of the virus in
vivo. Greater than 90% of the human population is be-
nignly infected for life. The persistent infection is only ap-
parent as stable levels of viral shedding in the saliva (3) and
infected cells in the blood (4) and lymphoid tissue. Further-
more, persistently infected cells in vivo bear no resem-
blance to the proliferating blasts seen with in vitro infec-
tion. In the peripheral blood of healthy carriers, the virus is
restricted to latently infected (5), memory B cells (6) that
do not express the growth-promoting latent genes (7) and
are not phenotypically lymphoblastoid (8). The cells are
not proliferating, but resting in G
 
0
 
 (9) and do not constitute
a pathogenic threat. We have proposed (6, 10) that EBV
infects and activates B cells to become proliferating blasts in
vivo in order to differentiate into memory cells. This pro-
vides a mechanism for the virus to gain access to the mem-
ory compartment, which we have suggested as a site of
long-term persistence.
It is generally assumed that immunosuppression leads to
an increased number of latently infected cells in the blood.
However, this belief is based on two assays (11–17) that
both have significant limitations (for a discussion, see refer-
ence 8) such that it is only possible to conclude with cer-
tainty that there is a higher viral genome burden. Whether
this increased burden is due to an expansion of latently in-
fected cells, viral reactivation, or a combination of the two
is unknown. The proposed increase in latently infected
cells is believed to be in the form of B lymphoblasts. These
blasts are targets for cytotoxic T cells in healthy carriers
(18), but are thought to proliferate unchecked in the blood
when the cellular immune response is suppressed. The ex-
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pansion of these cells may lead to posttransplant lympho-
proliferative disease (PTLD),
 
1
 
 which ultimately can result
in tumors that resemble in vitro–infected B lymphoblasts
(for a review, see reference 14). These proliferating blasts
survive only because the immune response is compro-
mised, since PTLD usually resolves upon removing immu-
nosuppression (19). Surprisingly, most studies of EBV in
immunosuppressed patients have been restricted to a very
small subset of patients, namely those with PTLD. The
presence of EBV-infected lymphoblasts in the blood of im-
munosuppressed patients who lack overt PTLD has been
described only once and for a single patient (20). Given the
finding that EBV is restricted to memory cells in the pe-
ripheral blood of healthy carriers, we decided it was time to
reassess the status of virally infected cells in the peripheral
blood of immunosuppressed patients. We have used re-
cently developed methods to precisely quantitate and char-
acterize the infected cells in the blood of patients who were
immunosuppressed as a consequence of organ transplanta-
tion. The patient population was clinically healthy at the
time of study and showed no signs of PTLD. In this study,
we demonstrate unambiguously for the first time that there
is an expansion of latently infected B cells in the blood of
immunosuppressed patients who are otherwise clinically
healthy. The cells are not infected proliferating lympho-
blasts, but rather the same population of resting, memory B
cells found in healthy carriers. The only exception is that
viral reactivation is frequently detected in the blood of im-
munosuppressed patients but not in healthy carriers. In
these cases, viral replication, not latently infected cells, pro-
vides the largest contribution to the increased genome burden.
 
Materials and Methods
 
Cell Lines and Primary Cells.
 
Namalwa (American Type
Culture Collection) is an EBV
 
1
 
 BL line containing one or two
copies of the viral genome. This was used as a positive control for
the EBV-specific DNA PCR. BJAB is an EBV
 
2
 
 B cell lym-
phoma used as a negative control for all PCR-related experi-
ments. For reverse transcriptase (RT)-PCR of latent membrane
protein (LMP)-2a, LMP-1, and EBV nuclear antigen (EBNA)-2,
the LCL line IB4 was used as a positive control. Rael, an EBV
 
1
 
BL line, was used as a positive control for EBNA-1(Qp) RT-
PCR. All cell lines were maintained in 5% CO
 
2
 
 with 10% FCS,
RPMI 1640 with penicillin and streptomycin.
Patients attending the Transplantation Clinic at the New En-
gland Medical Center were recruited for blood donation. The
patients, including both kidney and liver recipients, were usually
1–2 mo posttransplantation. They all received cyclosporin A or
FK506, combined with azathioprine, mycophenolate mofetil, or
sirolimus (Table I). All of the patients received prednisone and
were under active immunosuppression, but were otherwise clini-
cally healthy, at the time they were studied and showed no evi-
dence of PTLD. Healthy volunteers were recruited from Tufts
University School of Medicine. The patient and control popula-
tions were matched for age distribution, sex, and minority repre-
sentation.
 
Cell Fractionations.
 
PBMCs were isolated and fractionated
using the MACS
 
®
 
 (Miltenyi Biotec) cell separation system as de-
scribed previously (6). The antibodies and concentrations used
were 0.018 
 
m
 
g/ml anti-CD19–biotin, 0.015 
 
m
 
g/ml anti-IgD–
biotin (Southern Biotechnology Associates), 0.03 
 
m
 
g/ml anti-
CD23–biotin (The Binding Site), and 1 
 
m
 
g/ml each goat anti-IgG,
 
1
 
Abbreviations used in this paper:
 
 EBNA, EBV nuclear antigen; LMP, latent
membrane protein; PTLD, posttransplant lymphoproliferative disease;
RT, reverse transcriptase; sIg, surface Ig.
 
Table I.
 
Summary of the Patients Described in This Study
 
Patient
 
*
 
Organ Rejection
 
‡
 
Immuno-
suppression
 
§
 
Antiviral
 
i
 
Primary Secondary
1 Liver
 
1
 
FK AZA Ga
2 Liver
 
1
 
CSA MMF Ga
3 Liver
 
1
 
FK MMF Ga
4 Kidney
 
1
 
CSA AZA
 
2
 
5 Liver
 
2
 
CSA AZA Ac
6 Liver
 
2
 
CSA MMF Ga
7 Liver
 
1
 
CSA AZA Ga
8 Kidney
 
1
 
CSA MMF
 
2
 
9 Liver
 
2
 
CSA AZA Ac
10 Kidney
 
1
 
FK AZA Ac
11 Liver
 
1
 
CSA AZA Ac
12 Kidney
 
2
 
FK SIR Ac
13 Liver
 
2
 
CSA AZA Ga
14 Kidney
 
2
 
CSA AZA Ga
15 Kidney
 
1
 
FK AZA Ac
16 Liver
 
2
 
FK AZA Ga
17 Liver
 
1
 
CSA AZA
 
2
 
18 Liver
 
2
 
FK AZA Ga
19 Kidney
 
1
 
CSA AZA Ga
20 Kidney
 
2
 
CSA AZA Ac
21 Liver
 
1
 
CSA AZA Ga
22 Kidney
 
2
 
CSA SIR Ga
23 Liver
 
1
 
FK AZA Ga
24 Liver
 
1
 
FK AZA Ga
25 Liver
 
2
 
FK AZA Ga
26 Liver
 
1
 
FK AZA Ga
27 Liver
 
2
 
CSA AZA Ga
28 Liver
 
2
 
FK AZA Ga
 
*
 
At the time of study, all patients were clinically healthy. Patients are
listed in descending order of frequency of virus-infected cells in the pe-
ripheral blood. For frequencies, see Table V.
 
‡
 
Indicates patients had (
 
1
 
) or had not (
 
2
 
) experienced an episode of
graft rejection.
 
§
 
All patients received combination immunosuppression consisting of
steroids together with a primary and a secondary immunosuppressant.
CSA, cyclosporin A; FK, FK506; AZA, azathioprine; MMF, mycophe-
nolate mofetil; SIR, sirolimus.
 
i
 
Designates patients who had received antiviral treatment at some
point. Ga, gancyclovir; Ac, acyclovir; 
 
2
 
, no antiviral. 
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-IgA, and -IgM (Southern Biotechnology Associates). Positively
selected fractions were typically 
 
.
 
90% pure for the desired
marker. Contamination of a specific B cell population with an
undesired B cell population was always 
 
,
 
5%.
 
FACS
 
®
 
 Analysis and Antibodies.
 
Fractionated populations
were analyzed on a Becton Dickinson FACScan™ using Lysis II
Software. Anti-CD20–FITC (Dako), a pan-B cell marker, and
anti-IgD–PE (The Binding Site) were used to assay the purity
and depletion of the desired populations. MOPC21 (IgG1 iso-
type control; Sigma Chemical Co.) and MOPC121 (IgG2b iso-
type control; Sigma Chemical Co.) were used as negative con-
trols.
 
EBV-specific DNA PCR.
 
Isolated populations were distrib-
uted to the wells of a V-bottomed microtiter plate (Nunc) at the
desired cell number. The cells were pelleted, the cell pellets lysed,
and the extract subjected to DNA PCR specific to the W repeat
region of the EBV genome exactly as described previously (6).
PCR products were resolved on a 2% Nuseive agarose (FMC
Corp.), 1% Seakem LE agarose (FMC Corp.) gel, and Southern
blotted to Nytran Plus as described by the manufacturer (Schlei-
cher and Schuell). Specific products were detected using random
primed labeled, purified PCR product from Namalwa cells as de-
scribed previously (6).
 
Cell Cycle Analysis.
 
Analysis of the cell cycle status of a given
population was performed by labeling cells with propidium io-
dide in the presence of the nonionic detergent Triton X-100 ex-
actly as described previously (9). The cells were sorted based on
DNA content using a Becton Dickinson FACStar
 
Plus™
 
, into a V-bot-
tomed microtiter plate. DNA PCR was performed as described
above.
The calculation of expected versus observed numbers of EBV-
infected cells in the S-G
 
2
 
-M B cell populations has been de-
scribed previously (9) and was performed as follows. In Table III,
we used the measured frequency of EBV-infected B cells in the
G
 
0
 
-G
 
1
 
 population to estimate the expected frequency of EBV-
infected cells in the S-G
 
2
 
-M population if all of the infected cells
were proliferating and therefore all of the positive cells in the G
 
0
 
-
G
 
1
 
 fraction were in G
 
1
 
. This number was then compared with
the number of signals obtained experimentally. To make the esti-
mate, the following calculation was performed taking patient 2
from Table III as an example:
1.07% of the B cell population was in S-G
 
2
 
-M. Therefore, for
every 10
 
6
 
 G
 
0
 
-G
 
1
 
 B cells, there are 1.07/99 
 
3
 
 10
 
6
 
 
 
5 
 
1.08 
 
3
 
 10
 
4
 
cells in S-G
 
2
 
-M. The frequency of EBV-infected cells was 800/
10
 
6
 
 in the G
 
0
 
-G
 
1
 
 population. In a typical cycling EBV
 
1
 
 lympho-
blastoid cell line, the percentage of cells in S-G
 
2
 
-M is 45 
 
6 
 
4%.
Therefore, if we assume that the EBV-infected cells have a similar
cell cycle distribution, then for every 800 EBV
 
1
 
 G
 
0
 
-G
 
1
 
 cells there
should be 45/55 
 
3
 
 800 
 
5 
 
655 EBV
 
1
 
 cells in S-G
 
2
 
-M. There-
fore, we should find 655 EBV
 
1
 
 cells in 1.08 
 
3
 
 10
 
4
 
 S-G
 
2
 
-M cells.
In this experiment, we analyzed a total of 6 
 
3
 
 10
 
2
 
 S-G
 
2
 
-M cells.
Therefore, we expect 655 
 
3
 
 (1.08 
 
3
 
 10
 
4
 
)/(6 
 
3
 
 10
 
2
 
) 
 
5 
 
36 in-
fected cells in the S-G
 
2
 
-M population we tested. We actually ob-
tained two signals.
 
Gardella Gel Analysis.
 
To resolve linear viral genomes from
circular viral genomes, the hallmarks of lytic and latent infection,
respectively, PCR-modified Gardella gel analysis was used as de-
scribed previously (5). In brief, whole cells are lysed in situ in the
wells of a 0.75% low melt agarose gel, and the linear and episomal
forms of the genome are separated based on their differential mo-
bility in agarose gels: linear genomes migrate faster because they
“snake” through the gel. The lanes were sliced into sections, and
the agarose from each slice was digested using 
 
b
 
-agarase (FMC
 
Corp.). DNA was precipitated, and EBV-specific DNA PCR
was performed for each slice as described above. The relative mi-
gration points for linear and circular DNA were identified using
virions and PBL B cells, respectively, as controls.
 
RNA Purification and RT-PCR.
 
RNA was isolated from 5
 
3 
 
10
 
6
 
 primary cells or 2 
 
3 
 
105 culture cells, and cDNA synthesis
was performed as described previously (6). 5 ml of cDNA was
then used in PCR for EBNA-1(Qp), EBNA-2, LMP-1, and
LMP-2a. This allowed us to test for all four transcripts from one
pot of cDNA. EBNA-1(Qp) PCR was carried out using the am-
plimers described by Schaefer et al. (21). Reaction concentrations
were 50 mM KCl, 20 mM Tris, pH 8.3, 2.5 mM MgCl2, 0.2 mM
dNTPs, and 20 mM of each primer. Reaction conditions were 15 s
at 958C, 30 s at 628C, and 30 s at 728C for 40 cycles, followed by
a 5-min 728C extension step. For EBNA-2 PCR, amplimers de-
scribed by Chen et al. were used (22). Reaction concentrations
and temperature conditions were the same as for EBNA-1(Qp).
LMP-1 PCR amplimers were as described by Chen et al. (22),
and reaction concentrations were 50 mM KCl, 20 mM Tris, pH
8.3, 3.0 mM MgCl2, 0.2 mM dNTPs, 20 mM each primer. Re-
action conditions were 958C for 15 s, 658C for 30 s, and 728C for
30 s, followed by a 5-min 728C extension step. LMP-2a PCR
amplimers were as described by Tierney et al. (23), and reaction
concentrations were 50 mM KCl, 10 mM Tris, pH 8.3, 2.0 mM
MgCl2, 0.2 mM dNTPs, and 20 mM of each primer. Tempera-
ture conditions were 958C for 15 s, 558C for 30 s, and 728C for
45 s for 40 cycles, followed by a 5-min 728C extension step.
PCR products were electrophoresed on 2% Nuseive agarose
(FMC Corp.), 1% Seakem LE agarose (FMC Corp.) gel, and
Southern blotted to Nytran Plus as described by the manufacturer
(Schleicher and Schuell). Products were detected by probing
with the appropriate purified PCR product (from Rael for
EBNA-1, and from IB4 for EBNA-2, LMP-1, and LMP-2a) that
was random primed labeled (Boehringer Mannheim) as described
by the manufacturer. In every case, it was possible to detect the
mRNA from a single infected cell (IB4 or Rael) in the presence
of 5 3 106 uninfected PBL B cells.
Results
The Infected Cells in the Blood of Immunosuppressed Patients
Are Memory B Cells. To identify the type of latently in-
fected cells in the peripheral blood of immunosuppressed
patients, we first characterized their cell surface phenotype.
PBLs were fractionated using biotinylated antibodies and
the MACS® magnetic bead technique. The antibodies used
recognized CD19, a pan-B cell marker; CD23, a marker
expressed on naive B cells and strongly expressed on B cell
blasts activated by EBV infection; IgD, which is expressed
only on naive B cells; and the A, G, and M isotypes of Ig,
which are expressed on the surface of memory cells in the
absence of IgD.
In the first round of experiments, CD19 was used to separate
the B and non-B cell populations, and an anti–IgG1IgA1IgM
antibody was used to separate cells expressing surface Ig
(sIg) from those lacking sIg. The frequency of virus-
infected cells in each population was then assayed by limit-
ing dilution DNA PCR. An example of one experiment
for each marker is shown in Fig. 1, and a summary of the
quantitation for two patients for each marker is shown in570 EBV in the Immunosuppressed
Table II. As expected, essentially all of the virus-infected
cells were B cells (CD191) expressing sIg. Less than 1% of
the infected cells were in the non-B (CD192) sIg2 com-
partment. This number was so small, it could be accounted
for by low levels of contamination of the CD192 cells with
B cells. The B cells (CD191) were then further fractionated
on the basis of IgD expression to see if there were infected
cells in the naive compartment, and CD23 expression to
test if the infected cells expressed the lymphoblastoid phe-
notype. The results of one experiment for each marker are
shown in Fig. 1, and the quantitation for two patients with
each marker is summarized in Table II. Essentially all of the
infected cells reside in the CD232 and IgD2 populations.
There was no significant number of infected cells detected
in either the CD231 or IgD1 populations. This is not the
expected phenotype of a B lymphoblast. Rather, it is the
same as the latently infected cells found in the blood of
healthy carriers—memory B cells. Therefore, we conclude
that the surface phenotype of infected cells in the periph-
eral blood of immunosuppressed individuals is the same as
that found in healthy carriers.
The Infected Memory Cells Are Resting. The cell surface
phenotype of the infected cells in the blood of immuno-
suppressed individuals, CD191sIg1IgD2CD232, is the
same as that found for healthy carriers, namely resting,
memory B cells (6). To confirm that the infected cells in
immunosuppressed patients were indeed resting, purified B
cells were permeabilized and stained for DNA content with
the dye propidium iodide. The cells were fractionated on
the basis of DNA content into G0/G1 and S/G2/M popula-
tions, and the frequency of virus-infected cells in each pop-
ulation was assessed. The results of three such experiments,
on patients with widely ranging frequencies, are summa-
rized in Table III. Only a small fraction, z1%, of the pe-
ripheral blood B cells were in S/G2/M. This is probably a
result of the immunosuppressive drugs. If the virus-infected
cells were in cycle, there should be a large enrichment of
virus-positive cells in the S/G2/M population. However,
EBV was not found in the S/G2/M population of B cells
from immunosuppressed patients. In fact, so few positive
signals were obtained from the S/G2/M population that it
was impossible to measure a frequency. This was not an ar-
tifact of the techniques used, because EBV-infected lym-
phoblasts could be quantitatively detected in the S/G2/M
population when spiked into the peripheral B cells before
analysis (not shown, and reference 9). The frequencies of
infected cells in the G0/G1 populations could be measured
and were indistinguishable from the values obtained for the
unfractionated cells. These results imply that most or all of
the virus-infected cells are in the G0/G1 population. To
further quantitate the accuracy of this conclusion, we used
the frequency of virus-infected cells, measured in the G0/G1
Figure 1. The cell surface phenotype of EBV-infected cells in the
blood of immunosuppressed individuals. Peripheral lymphocytes were
fractionated using mAbs and the MACS® separation technique. For
CD19 and sIg, whole PBMCs were fractionated for the specific marker.
For CD23 and IgD, the cells were first selected for expression of the de-
sired marker and the remaining marker-negative B cells were then se-
lected using the pan-B cell marker CD19. The cells were serially diluted,
and replicates of each dilution were subjected to DNA PCR for the W
repeat of the viral DNA using a technique that will detect a single viral
genome in 106 uninfected cells (reference 4). The PCR products were
detected by Southern blotting with a specific probe for the W repeat. The
position of each lane containing a sample is indicated at the top. Two
negative and one positive control were performed for each dilution of
cells (not shown). For full experimental details, see Materials and Meth-
ods. The frequency of virus-infected cells was calculated using Poisson
statistics, and the results are summarized in Table II. The cell surface phe-
notype of the cells tested, the number of cells tested per sample, and the
fraction of samples positive at each cell number are given.
Table II. The Cell Surface Phenotype of EBV-infected Cells in the 
Peripheral Blood of Immunosuppressed Patients
Cell type Patient
Frequency*
Enriched Depleted
CD19 3 .6,100 10
7 1,550 ,10
sIg 16 750 ,8
18 400 ,1
CD23 3 360 .10,000
23 ,12 925
IgD 4 ,10 3,100
14 60 1,800
*The frequencies are expressed as the number of infected cells per 107
total cells. We have shown previously that the error in the estimates is
#30%.571 Babcock et al.
population, to predict the number of positives we would
expect to find in the S/G2/M population if the cells had
been in cycle. This is the same analysis we have used for
healthy donors (9). As can be seen from Table III, the sig-
nals obtained represented z5% of those expected or z10%
of the cells in cell cycle (taking into account the cycling
cells in G1). Therefore, we estimate that $90% of the in-
fected cells are resting. We conclude that the population of
EBV-infected cells found in the peripheral blood of immu-
nosuppressed patients has the phenotype of resting, mem-
ory B cells.
Viral Replication Is Frequently Detected in the Blood of Im-
munosuppressed Patients. If the phenotype of infected cells
in the blood of immunosuppressed individuals is un-
changed from that found in healthy carriers, can we be sure
that the number of infected cells is changed? Previous stud-
ies could not distinguish whether there was truly an in-
crease in the number of infected cells or simply an increase
in the fraction of cells replicating the virus. Therefore, we
decided to test the relative contributions of latent and lytic
genomes to the viral burden. This was done by using a
technique, DNA PCR–modified Gardella gels, that can
distinguish the linear form of the viral genome, characteris-
tic of cells replicating the virus, from the circular or episo-
mal form characteristic of latent infection. Using this ap-
proach, we have shown that infection in the peripheral
blood of healthy carriers is tightly latent (7 of 7 tested),
with no viral replication detected (5). An example of such
an analysis on a healthy carrier is shown in Fig. 2 A, and the
results for virion DNA, which is linear, are shown in Fig. 2
B for comparison. The results for two immunosuppressed
patients are shown in Fig. 2, C and D, and a summary of all
the patients tested is shown in Table IV. It is apparent from
these studies that in half the patients (nos. 1, 8, 11, and 15),
all of the cells are latently infected (Fig. 2 C, for example).
However, the other patients (nos. 10, 12, and 17) demon-
strated a substantial number of linear genomes (Fig. 2 D,
for example) in addition to the latent episomal genomes.
Comparison of the relative signals in the episomal and lin-
ear location indicates that linear genomes were the major
contributor to the viral genome burden in these individu-
als. Our analysis cannot distinguish the fraction of cells that
Table III. Analysis of the Cell Cycle Status of EBV-infected Cells in the Peripheral Blood of Immunosuppressed Patients
Patient Frequency*
Frequency in
G0-G1
‡ Percent S-G2-M§
No. of S-G2-M
cells testedi
No. observed
in S-G2-M¶
No. expected
in S-G2-M**
2 8,100 8,000 1.07 600 2 36
9 1,500 1,200 0.6 2,040 2 33
18 200 260 1.22 8,800 1 34
Total
58 3
*The frequencies are expressed as the number of infected cells per 107 total B cells and are taken from Table V. We have shown previously that the
error in the estimates is #30%.
‡The frequency of virus-infected cells detected in the sorted G0/G1 population.
§The percentage of all B cells in the S/G2/M gate for the sort.
iThe total number of S/G2/M cells sorted for limiting dilution analysis.
¶The total number of PCR signals obtained in the DNA PCR limiting dilution analysis of the S/G2/M cells.
**The number of signals expected in the S/G2/M analysis if all of the infected cells were in cycle. For details, see Materials and Methods and reference 9.
Figure 2. Gardella gel analysis of peripheral B cells from immunosup-
pressed individuals. The gel resolves the faster running linear genomes
from slower running episomal genomes. Each sample lane was excised
and cut into a series of slices. DNA was extracted from each slice and sub-
jected to EBV-specific DNA PCR. The PCR products from each gel
slice were detected by Southern blotting. The position of each lane is in-
dicated at the top. The location of the top and bottom slices of the
Gardella gels and the expected migration point of linear and episomal
forms of the genome are indicated. The expected location of the PCR
product is shown by an arrow. For full experimental details, see Materials
and Methods. (A) Analysis of peripheral blood B cells from a healthy car-
rier as a positive control for the migration of episomes. It has been shown
previously that only the episomal form of the virus is detected in these
samples. (B) Analysis of whole EBV virions as a positive control for the
migration of the linear form of the genome. (C) Analysis of peripheral
blood B cells from an immunosuppressed individual who only carries la-
tently infected cells. (D) Analysis of peripheral blood B cells from an im-
munosuppressed individual who has both the latent (episomal) and lytic
(linear) forms of the viral genome.572 EBV in the Immunosuppressed
might be replicating the virus. However, comparison with
results obtained with cell lines (5, 24) suggests that the rela-
tive ratio of linear and episomal genomes could be ac-
counted for by a very small (,10%) fraction of the cells
replicating the virus at any one time. We do not believe
that failure to detect linear genomes in some patients repre-
sents a sampling variation or that the appearance of linear
genomes is an artifact due to shearing, since when certain
patients were retested, the same results were obtained. For
example, patient 8 was tested three times over the course of
8 mo under continuous immunosuppression, and never
showed detectable levels of linear genomes. The detection
of linear genomes was not a function of the number of in-
fected cells present, since the same number of B cells was
loaded into the gel for each patient tested, yet there was no
correlation between the frequency of infected cells and the
presence of linear genomes (Table IV).
We conclude from these studies that in approximately
half of the patients studied, the viral genome burden can be
entirely accounted for by latently infected cells. However,
the remaining patients have both latently and lytically in-
fected cells, with linear genomes contributing the largest
component of the viral genome burden.
The Absolute Number of EBV-infected Cells Increases after
Immunosuppression. Previous studies have claimed that im-
munosuppression leads to an increase in the number of la-
tently infected cells in the blood. However, these studies
have relied on assays that could not distinguish an increase
in the infected cell number from an increase in the fraction
of cells replicating the virus. We have now shown that the
infected cells are not proliferating, and that viral replication
is a frequent occurrence in the blood of immunosuppressed
patients. Therefore, it was possible that there was no
change in the number of infected cells and that the previ-
ously described increase in viral burden was entirely due to
increased rates of reactivation. We decided to definitively
resolve this issue by precisely quantitating the number of
virus-infected cells using the limiting dilution DNA PCR
assay we have described previously (4). Because this assay
involves the titration and detection of intact infected cells,
it provides a measure of the number of virus-infected cells
that is independent of the number of viral genomes per cell
and therefore will not be artifactually biased by lytically in-
fected cells that have high genome copy numbers. The re-
sults from 28 immunosuppressed allograft patients are sum-
marized in Table V. As shown previously, the frequency
distribution in healthy carriers is skewed; therefore, it is not
possible to calculate a meaningful mean value or standard
deviation for comparison between populations. However,
Table IV. Detection of the Episomal and Linear Forms of the 
EBV Genome Characteristic of Latent and Lytic
Infection, Respectively
Patient Frequency* Episomal Linear
1 16,700 12
8 1,500 12
10 1,400 11
11 1,300 12
12 1,000 11
15 800 12
17 670 11
*The frequencies are expressed as the number of infected cells per 107
total B cells. We have shown previously that the error in the estimates is
#30%.
Table V. Comparison of the Frequencies of EBV-infected B Cells 
in the Peripheral Blood of Healthy Controls and
Immunosuppressed Patients
Control* Frequency‡ Patient Frequency‡
1 425 1 16,700
2 320 2 8,100
3 110 3 6,500§
4 95 4 5,200
5 90 5 2,900
6 85 6 1,700
7 85 7 1,550
8 75 8 1,500
9 55 9 1,500
10 50 10 1,400
11 40 11 1,300
12 30 12 1,000
13 30 13 1,000§
14 30 14 825
15 25 15 800
16 25 16 750
17 25 17 670
18 15 18 400
19 10 19 300
20 0i 20 200
21 0i 21 100
22 70
23 62
24 50¶
25 40
26 25¶
27 8¶
28 3¶
*The data set for the control group is an enlarged version of a previ-
ously published set (reference 4).
‡The frequencies are expressed as the number of infected cells per 107
total B cells. We have shown previously that the error in the estimates is
#30%.
§Probable underestimate due to too many signals.
iConfirmed serologically to be EBV2.
¶Estimate due to insufficient signals.573 Babcock et al.
the data show a normal distribution when the ln frequen-
cies are derived (Fig. 3 A); this allows the calculation of
mean and standard deviation for the ln frequencies. The
mean frequency of the ln values for healthy donors is 3.96.
Calculating the anti-ln, this is 50 infected cells per 107 B
cells, in agreement with our previously published estimates
on a smaller subset of healthy carriers (4). When this analy-
sis was applied to the data set from immunosuppressed pa-
tients, it was apparent that there are two discrete groups
(Fig. 3 A). The first, represented by patients 1–19, also
demonstrated a normal distribution of the ln frequencies,
with a standard deviation indistinguishable from that of the
healthy carriers (0.95 vs. 1.02). The mean frequency of the
ln values was 7.36 or, from the anti-ln, 1,600 infected cells
per 107 B cells, representing a 30-fold increase over the
healthy carriers. The fraction of B cells in these patients
varied from normal to z10% of normal, but in no case
could the increase in the frequency of infected cells be ac-
counted for by selective loss of uninfected cells. Therefore,
we may conclude that there was also an increase in the abso-
lute numbers of virus-infected cells. The relative ratio of naive
to memory B cells, as judged by sIgD expression, was not dif-
ferent from the control population (Fig. 3 B). To confirm that
there was an increase in infected cells due to immunosuppres-
sive drugs, the frequency of virus-infected cells was tested in
several patients before and after immunosuppression. In ev-
ery case, the frequencies before immunosuppression were
within the range observed for the control population, and
after immunosuppression the frequencies were higher than
the highest value seen with the controls (not shown).
The second group is represented by patients 20–28. Al-
though too small to draw precise conclusions, this group
had a mean frequency of virus-infected cells (36 vs. 50)
similar to the healthy controls. The simplest interpretation
is that this group of patients did not respond to the immu-
nosuppressive drugs; however, they did not show elevated
rates of rejection. Confirmation that this was a discrete
population came from the observation that they exhibited a
large increase in the numbers of uninfected naive B cells
(Fig. 3 B; three to six times that in the controls), which was
never seen in the high frequency group. This increase
counterbalanced a modest increase in infected memory
cells, resulting in no overall change in the frequency of vi-
rus-infected B cells. We have attempted to correlate the
status of the two groups of patients with medications, type
and origin of the transplanted organ, diagnosis at the time
of transplant, sex, ethnicity, and occurrence of rejection
episodes. The only factor that correlated was the use of
mycophenolate mofetil with the occurrence of high fre-
quencies of virus-infected cells (see Table I). No factor
could be associated specifically with the low frequency pa-
tients.
We conclude that there is an increase in the frequency of
infected B cells in the blood of only two thirds of patients
receiving immunosuppressive drugs at the New England
Medical Center.
Viral Gene Expression. RT-PCR analysis of virally in-
fected cells from the peripheral blood of healthy carriers
suggests that the only viral latent genes detected are LMP-2a
and possibly EBNA-1 (7, 9, 22, 23), although the latter re-
sult is controversial. LMP-2a contains the same signaling
immunoreceptor tyrosine-based activation motif (ITAM)
found in the B cell receptor (25). Because of this, we have
suggested that LMP-2a could play a role in the long-term
Figure 3. Frequencies of vi-
rus-infected cells in healthy con-
trol and immunosuppressed pop-
ulations. (A) The graphs show
the distribution in the frequen-
cies for each population plotted
as their ln values. The resulting
curve, for healthy donors, ap-
proximates a normal distribution
with a mean frequency of 50 in-
fected cells per 107 B cells. The
immunosuppressed patients fall
into two groups with means of
36 and 1,600, respectively. (B)
FACS® analysis of representative
individuals from the healthy
controls and from each group of
immunosuppressed patients. Note
that the level of IgD1 B cells in
the representative high frequency
patient (6.4%) is within the nor-
mal range compared with the
healthy control (7.2%), whereas
it is highly elevated in the low
frequency patient (24.7%). In
comparison, the memory cells
(IgD2CD201) are within normal
range for both patients (1.4 and
2.1 vs. 1.9% in the control).574 EBV in the Immunosuppressed
maintenance of the infected memory cells by supplying a
surrogate B cell receptor survival signal (6). Immunosup-
pressed individuals also carry the virus in the resting mem-
ory population, but at a higher frequency. Therefore, we
expected to detect LMP-2a with ease in these individuals.
However, as shown in Table VI, LMP-2a was only found
in one of the four patients tested, and this was the patient
with the highest frequency of virus-infected cells. The re-
sults for two patients are shown in Lanes A and C of Fig. 4,
and the results for all four patients are summarized in Table
VI. Lane A shows the result from a patient whose cDNA
was tested from a pool of peripheral blood B cells estimated
to contain z20 infected cells. No LMP-2a message was de-
tected. Lane C is from a patient whose B cell sample was
estimated to contain z1,700 infected cells. In this case, the
signal obtained had an intensity lying between that ob-
tained with one and five cells from the EBV-immortalized
cell line IB4 (lanes B or D vs. E). The cell line IB4 was
used as a positive control because, in studies not shown, the
RT-PCR signal obtained for LMP-2a was similar for IB4
and a number of other in vitro–immortalized lymphoblas-
toid lines. Note that in control studies, performed for every
RT-PCR, the LMP-2a message can be readily detected in
a single cell from the IB4 cell line in the presence of 5 3
106 uninfected PBL B cells (lane E). The negative PCR
signals obtained were not due to an artifact or inhibitory
contaminants in the samples, because we could readily de-
tect five IB4 cells when they were mixed with the patient
cells before analysis (see lane B, for example). cDNA from
the LMP-2a2 patients was also tested for expression of the
EBNA-2 gene, which is required for expression of the full
panoply of latent genes found in the lymphoblastoid type of
latent infection, and EBNA-1(Qp), which is derived from a
unique promoter that allows the expression of EBNA-1
only in Burkitt lymphoma cells. Again, no signal was ob-
tained, although the techniques readily detected a single
spiked EBV-infected cell, IB4 for EBNA-2 and Rael for
EBNA-1(Qp), in the presence of 5 3106 uninfected PBL
B cells. These results suggest that the vast majority of in-
fected cells in the blood of immunosuppressed individuals
may be transcriptionally silent for the known latent genes.
Discussion
The main conclusion of this paper is that latently in-
fected resting, memory B cells expand in the peripheral
blood of immunosuppressed individuals. This surprising re-
sult means that there is no expansion of EBV-infected pro-
liferating lymphoblasts in the blood, as had been thought
previously.
Most previous studies on the increased viral burden in
the immunosuppressed have focused on the small subpopu-
lation of individuals that have PTLD, whose systems are
perturbed not only by immunosuppression but also by the
presence of malignancy. This is the first study to character-
ize the phenotype of cells that expand in the periphery of
patients that are immunosuppressed but otherwise clinically
healthy. In fact, this is the first study to demonstrate quanti-
tatively that the number of latently infected cells increases
in the peripheral blood of most, but not all, patients after
immunosuppression and that the cells are all B lympho-
cytes. The limitations of the previous studies are best ex-
emplified by our demonstration that in approximately half
of the patients studied, viral replication contributes a larger
portion of the viral genome burden than does the increase
in latently infected cells (compare linear and episomal signal
intensity in Fig. 2 D).
Our results cannot exclude the possibility that small
(,10%) numbers of proliferating infected lymphoblasts are
present in the peripheral circulation. We have attempted to
confirm the presence of these cells by testing enriched
CD231 B cells for expression of EBNA-2 and LMP-1, la-
tent genes characteristically expressed in the lymphoblas-
toid form of latency. However, we have only detected ex-
pression of these genes in one out of eight patients tested.
Therefore, it seems likely that in most patients the small
numbers of infected cells detected by DNA PCR in the
CD231 and cycling populations are due to low levels of
cross-contamination.
We have shown previously that EBV-infected cells in
the peripheral blood of healthy carriers are restricted to the
Figure 4. RT-PCR analysis for the expression of LMP-2a mRNA in
infected B cells from immunosuppressed individuals. CD191 B cells were
purified by the MACS® system. RNA was extracted using Trizol, and
RT-PCR was performed for LMP-2a. (A) cDNA from a sample contain-
ing an estimated 20 infected cells from patient 25. (B) As in A, but spiked
with five cells from the EBV-immortalized lymphoblastoid cell line IB4.
(C) cDNA from a sample containing an estimated 1,700 infected cells
from patient 6. (D) cDNA from 5 IB4 cells in 2 3 105 EBV2 BJAB cells.
(E) cDNA from 1 IB4 cell in 2 3 105 EBV2 BJAB cells. (F) cDNA from
2 3 105 EBV2 BJAB cells.
Table VI. Expression of the EBV-encoded LMP-2a Gene in 
Peripheral Blood Cells from Immunosuppressed Patients
Patient
No. of EBV1
cells tested* LMP-2a EBNA-2 EBNA-1 (Qp)
6 1,700 1 ND ND
13 1,000 22 2
20 5 22 2
25 20 22 2
*The number of virus-infected cells was enhanced by prior enrichment
for CD232 B cells.575 Babcock et al.
memory compartment. This cannot be because infected
naive cells are preferentially lysed by CTLs, because we
have now shown that a similar restriction applies even after
immunosuppression. Therefore, some other mechanism
must account for the specific association of EBV with
memory cells in the peripheral blood. In addition, the
number and frequency of latently infected cells increase in
the periphery of immunosuppressed individuals, yet the
cells themselves are resting. Therefore, the production of
latently infected memory cells must occur elsewhere. The
explanation we favor is based on the idea that EBV uses the
normal pathways of B cell activation and differentiation to
establish and maintain a latent infection. In this model,
EBV-infected lymphoblasts are generated from newly in-
fected B cells in secondary lymphoid tissue such as the ton-
sil. We propose that these latently infected blasts behave
like normal B blasts and remain in the lymph nodes, where
they follow the normal pathways of B cell activation and
differentiation to gain access to the long-lived memory
compartment, which we have proposed as the site of long-
term persistence. Upon immunosuppression, there is more
infectious virus produced in the lymphoid tissue, and
therefore more cells are infected and become proliferating
lymphoblasts. These blasts expand due to the lack of a cel-
lular immune response, and eventually leave the lymph
nodes as increased numbers of differentiated memory B
cells. If our hypothesis is correct, then EBV-associated hy-
perproliferation due to an impaired CTL response should
also be limited to the lymph nodes. This is what is observed
with PTLDs, the majority of which are limited to the
lymph nodes and disappear when immunosuppression is
lifted (26). Escape from the lymph nodes into the periph-
eral circulation would be atypical behavior for a B blast,
and would be expected to be associated with the acquisi-
tion of genetic defects. Consistent with this, extranodal
PTLDs are less common, associated with genetic anoma-
lies, more malignant, and less likely to respond to reduc-
tions in immunosuppression (26).
A second, but not mutually exclusive, explanation for
the results in this paper is that the latently infected resting
memory B cells are themselves under immunosurveillance,
for example due to expression of LMP-2a (27). An im-
peded CTL response would allow higher numbers of these
cells to be tolerated. The RT-PCR analysis presented here
argues against this possibility. Although we can detect
LMP-2a message in mixtures where one IB4 cell is diluted
with 5 3 106 uninfected PBL B cells, we were unable to
detect it in as many as 1,000 infected cells from immuno-
suppressed patients. This suggests either that the transcript
copy number in the resting memory cells is extremely low
or that the major population that expands in the immuno-
suppressed is transcriptionally silent for LMP-2a. We have
also failed to detect two other markers of latent gene ex-
pression, EBNA-2 and EBNA-1(Qp). EBNA-2 is essential
for the expression of all the latent genes expressed in the
lymphoblastoid form of latency. Its absence was expected,
since EBNA-2 activity would be inconsistent with the rest-
ing state of the cells. These results suggest that the major
infected population in the blood of immunosuppressed pa-
tients may not express the known latent proteins and can-
not therefore be detected by immunosurveillance.
The one major difference in the behavior of the virus
between healthy carriers and immunosuppressed patients is
the presence of viral replication in the peripheral blood of
some patients. We have not tested our patients for lytic
gene expression; however, Prang et al. (28) reported find-
ing immediate early and early but not late transcripts of the
lytic cycle in the peripheral blood of healthy carriers. This
is consistent with our finding that viral genome replication
is not detectable. They also demonstrated strong CTL re-
sponses to the immediate early proteins (29) and proposed
that cells in the periphery occasionally enter the lytic cycle
spontaneously, but are eliminated by CTLs before they
produce infectious virus. A direct prediction of this idea is
that upon immunosuppression a small fraction of the in-
fected cells in the peripheral blood will spontaneously rep-
licate the virus, and indeed this is what we have found.
In conclusion, we have shown that immunosuppression
does not lead to the appearance of latently infected blasts in
the blood. Furthermore, our experiments lend further sup-
port to the idea that EBV has evolved to efficiently exploit
the normal biology of B lymphocytes to establish and
maintain latency in the memory compartment.
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